Recursion Pharmaceuticals (RXRX) said Tuesday the first patient has been dosed in a phase 1 clinical study of REC-3565 for the potential treatment of relapsed or refractory B-cell lymphomas.
The investigational drug has demonstrated evidence of durable tumor regression in preclinical trials as a monotherapy and in combination with a BTK inhibitor, the company said.
The two-part study will also evaluate REC-3565 as a monotherapy to identify a recommended dose for combination regimens, Recursion Pharmaceuticals added.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。